Compare Abbott Laboratories (ABT) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Stanley Black & Decker, Inc. — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Stanley Black & Decker, Inc. trades at $86.11 (market cap $13.89B). The key difference: Abbott Laboratories is far larger — about 12× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.71%). Which is the better fit depends on your goals.
| ABT | SWK | |
|---|---|---|
Market Cap | $166.94B | $13.89B |
Sector | Health | — |
52-Week High | $136.62 | $94.12 |
52-Week Low | $82.57 | $62.12 |
Enterprise Value | $193.69B | $20.06B |
Dividend Yield | 2.63% | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Stanley Black & Decker (SWK) trades at $89.37, down 2.75% today, with a bullish technical signal from moving averages but neutral oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue trends show stabilization around $15B annually, while net income improved to $401.9M in 2025. Debt reduction remains a priority, supported by positive operating cash flow of $971.2M.
SWK offers a turnaround story with improving profitability and shareholder returns via dividends, but faces headwinds from weak Tools & Outdoor demand and high debt levels. Analyst consensus is mixed with a $82.75 price target below current levels, suggesting cautious optimism amid execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
